Diabetic nephropathy;La ńephropathie diabétique

Revue Medicale de Liege

Volumn 60, Issue 5-6, 2005, Pages 479-486

  Weekers, L ^a   Krzesinski, J M ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Diabetic nephropathy; Epidemiology; Glucotoxicity; Hypertension; Renal failure

Indexed keywords

DIABETIC NEPHROPATHY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; HUMAN; INCIDENCE; PATHOPHYSIOLOGY;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; INCIDENCE;

EID: 21744440406     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Lippert J, Ritz E, Schwarzbeck A, et al.- The rising tide of endstage renal failure from diabetic nephropathy type II: an epidemiological analysis. Nephrol Dial Transplant, 1995, 10, 462-467.
2. Reach G, Altman J-J, Slama G, et al.- Causes and mechanisms of diabetic microangiopathy and neuropathy. The "glucose hypothesis" and its consequences. In: Vascular complications of diabetes (Eds Tchobroutsky G, Slama G, Assan R, Freychet P), Pradel, Paris, 1994, 53-62.
3. Brownlee M.- Biochemistry and molecular cell biology of diabetic complications. Nature, 2001, 414, 813-820.
4. Defraigne J.O.- Un mécanisme physiopathologique central à l'origine des complications du diabète? Rev Med Liège, 2005, 60, 472-478.
5. Fujisawa T, Ikegami H, Kawaguchi Y, et al.- Meta-analysis of association of insertion/deletion polymorphism of angiotensin 1-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia, 1998, 41, 47-53.
6. Esmatjes E, De Alvaro F.- Incidence of diabetic nephropathy in Type 1 diabetic patients in Spain: 'Estudio Diamante'. Diabetes Res Clin Pract, 2002, 57, 35-43.
7. Rossing P, Hougaard P, Parving HH.- Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care, 2002, 25, 859-864.
8. Chaturvedi N, Bandinelli S, Mangili R, et al.- Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int, 2001, 60, 219-227.
9. Lurbe E, Redon J, Kesani A, et al.- Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med, 2002, 347, 797-805.
10. Hadjadj S, Duly-Bouhanick B, Bekherraz A, et al.- Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metab, 2004, 30, 43-51.
11. Hadjadj S, Pean F, Gallois Y, et al.- Different patterns of insulin resistance in relatives of type 1 diabetic patients with retinopathy or nephropathy: the Genesis France-Belgium Study. Diabetes Care, 2004, 27, 2661-2668.
12. Chaturvedi N, Stephenson JM, Fuller JH.- The relationship between socioeconomic status and diabetes control and complications in the EURODIAB IDDM Complications Study. Diabetes Care, 1996, 19, 423-430.
13. Debacker N, Nobels F, Van Crombrugge P, et al.- Initiative pour la Promotion de la Qualité et Epidemiologie du Diabète sucré (IPQED): Rapport des résultats de l'enquête 2002. Institut Scientifique de santé publique, Bruxelles, 2004.
14. Lok CE, Oliver MJ, Rothwell DM, et al.- The growing volume of diabetes-related dialysis: a population based study. Nephrol Dial Transplant, 2004, 19, 3098-3103.
15. Stengel B, Billon S, Van Dijk PC, et al.- Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant, 2003, 18, 1824-1833.
16. Steno study group.- Effect of 6 months of strict metabolic control on eye and kidney function in insulin-dependent diabetics with background retinopathy. Lancet, 1982, 1, 121-124.
17. Hommel E, Parving HH, Mathiesen E, et al.- Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J (Clin Res Ed), 1986, 293, 467-470.
18. Perkins BA, Ficociello LH, Silva KH, et al.- Regression of microalbuminuria in type 1 diabetes. N Engl J Med, 2003, 348, 2285-2293.
19. Collins AJ, Frazier ET, Chen S-C, et al.- Trends in Incidence Rates for ESRD Secondary to Diabetes Mellitus (DM): The Potential Impact of Clinical Interventions to Slow CKD Progression (Abstract). J Am Soc Nephrol, 1995, (Suppl), SA-P040.
20. Weckers L, Scheen AJ, Lefèbvre PJ.- Comment j'explore ... la néphropathie diabétique. Première partie: micro- et macro-albuminurie. Rev Med Liège, 1998, 53, 494-498.
21. Weekers L, Scheen AJ, Rorive G.- Prévention de la néphropathie diabétique: de la microalbuminurie à l'insuffisance rénale. Rev Med Liège, 2003, 58, 297-306.
22. Weekers L, Krzesinski JM.- Rôle néphroprotecteur des antagonistes de l'angiotensine II dans le diabète de type 2: résultats des études IDNT et RENAAL. Rev Med Liège, 2001, 56, 723-726.
23. Atkins RC, Briganti EM, Lewis JB, et al.- Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis, 2005, 45, 281-287.
24. Krzesinski JM, Weekers L.- Hypertension et diabète. Rev Med Liège, 2005, 60, 572-577.
25. Barnett AH, Bain SC, Bouter P, et al.- Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med, 2004, 351, 1952-1961.
26. Ruggenenti P, Fassi A, Ilieva AP, et al.- Preventing microalbuminuria in type 2 diabetes. N Engl J Med, 2004, 351, 1941-1951.
27. Wolf G, Ritz E.- Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int, 2005, 67, 799-812.
28. Philips JC, Weekers L, Scheen AJ.- L'étude CALM évaluant l'effet d'un traitement combiné d'un inhibiteur de l'angiotensine de conversion et d'un antagoniste de du récepteur de l'angiotensine II dans la néphropathie diabétique. Rev Med Liège, 2001, 56, 126-128.
29. Rossert JA, Wauters JP.- Recommendations for the screening and management of patients with chronic kidney disease. Nephrol Dial Transplant, 2002, 17 (Suppl 1), 19-28.